

Nivolumab CheckMate 274

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Nivolumab CheckMate 274

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
 Therapeutic Indication: Adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection
 Experimental Arm: Nivolumab
 Control Arm: Placebo

